Published online before print January 19, 2004, doi: 10.1161/01.CIR.0000114521.88547.5E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;109:324-326.)
© 2004 American Heart Association, Inc.
Brief Rapid Communications |
Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac Muscle
Role of Nitric Oxide Synthase
From the University of Antwerp, Antwerp, Belgium.
Correspondence to Gilles W. De Keulenaer, MD, PhD, Laboratory of Physiology, University of Antwerp, Groenenborgerlaan 171, Building V, 6th Floor, 2020 Antwerp, Belgium. E-mail gilles.dekeulenaer{at}ua.ac.be
Received August 8, 2003; de novo received October 8, 2003; revision received December 10, 2003; accepted December 11, 2003.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Deficient cardiac neuregulin/ErbB signaling increases susceptibility to heart failure. In this study, we examined the effects of neuregulin-1 (NRG-1) on myocardial contractility.
Methods and Results— NRG-1 (
and ß isoforms) induced a negative inotropic effect in isolated rabbit papillary muscles and a rightward shift of the dose-response curve to isoproterenol. Both effects were attenuated by L-NMMA, which suggests a role for NO synthase. In cultured rat cardiomyocytes, NRG-1ß enhanced nitrite production and resulted in phosphorylation of endothelial NO synthase and the serine/threonine kinase Akt.
Conclusions— NRG-1 has negative inotropic effects that are preserved during ß-adrenergic stimulation and activates endothelial NO synthase in cardiomyocytes.
Key Words: neuregulin • nitric oxide synthase • endothelium • contractility • heart failure
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Monoclonal antibodies against the neuregulin (NRG) receptor ErbB2 (Trastuzumab), used in the treatment of breast cancer, may induce dilated cardiomyopathy and heart failure.1 From this observation, it was hypothesized that the NRG/ErbB pathway may participate in the pathogenesis of heart failure.
In the fetal heart, NRG-1 has been detected in endothelial cells, whereas ErbB2 and ErbB4 receptors are expressed throughout the myocardium. Targeted mutagenesis of NRG-1, ErbB2, or ErbB4 results in embryonic lethality due to failure of myocardial trabeculation.2,3 The ErbB3 receptor is present in endocardial cushion mesenchyme, and ErbB3-deficient mice exhibit cardiac cushion abnormalities.4 In the adult heart, ErbB2 and ErbB4 are found in the T-tubule system of cardiomyocytes, whereas NRG-1 is expressed in endocardial and microvascular endothelial cells.2 Conditional mutation of cardiac ErbB2 leads to dilated cardiomyopathy, which suggests a role for the NRG/ErbB pathway in heart failure.5
Experimental studies have shown that NRG-1 promotes survival and hypertrophic growth of adult cardiac myocytes in vitro.2,6 In the present study, we characterized the direct effects of NRG-1 on contractility of adult cardiac muscle and the possible contribution of the Akt-NO synthase (NOS) pathway in these effects.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mechanical Performance
Isometric contractions were recorded from papillary muscles isolated from the right ventricle of New Zealand White rabbits with an electromagnetic length-force transducer as described previously.7,8 After determination of the length at which peak twitch active tension is maximal (Lmax), stabilized muscles were randomly assigned to one of the following treatment protocols: (1) muscles kept in baseline conditions (control group), (2) muscles in which NRG-1
2 epidermal growth factor (EGF) domain (500 ng/mL or 71 nmol/L, Sigma; hereafter referred to as NRG-1) or NRG-1ß1 EGF domain (100 ng/mL or 13 nmol/L, Sigma; hereafter referred to as NRG-1ß) was added at time zero, or (3) muscles exposed to indomethacin (10 µmol/L, Merck Sharp & Dohme), L-NMMA (NG-methyl-L-arginine, acetate salt, 50 µmol/L, Sigma), or the tyrosine kinase inhibitor genistein (25 µmol/L, Sigma) 30 minutes before NRG-1 administration. Drug treatments were added to the solution bathing the muscle and remained present to the end of the experiment. Separate experiments were performed for cumulative dose-response curves for NRG-1ß (0.1 to 100 ng/mL). In separate experiments, cumulative concentration-response curves were constructed for isoproterenol (10 nmol/L to 10 µmol/L, Sigma) in control muscles and in muscles exposed to NRG-1 (100 ng/mL) or NRG-1ß (20 ng/mL) for 5 hours in both the presence and absence of L-NMMA.
Cell Isolation and Culture
Neonatal rat cardiac myocytes (NRCMs) were isolated from 1- to 2-day-old Harlan Sprague-Dawley rats and cultured as described previously.9 After 24 hours, cells were washed with Hank’s balanced salt solution and serum-starved for 24 hours before the experiments were begun.
Measurement of NO Production
NRCMs plated in 12-well culture plates at a density of 5x105 cells/well were exposed to NRG-1 for 24 hours, and medium was assayed for nitrite with the Griess reaction.10 L-NMMA was added to determine the role of NOS. Acetylcholine (Sigma) was used as a positive control. Protein content was determined with the Bradford assay.
Immunoprecipitation
Immunoprecipitation experiments were performed as described previously11 with slight modifications. Briefly, NRCMs were plated at a density of 4x106 cells per 100-mm dish and treated with NRG-1ß. Cells were harvested in lysis buffer with 0.2% Triton X-100, and lysates were incubated with anti-eNOS (endothelial NOS) antibody (Transduction Laboratories) bead (Sepharose A, Sigma) complexes. Pellets were washed and boiled in sample buffer before electrophoretic separation. Proteins were transferred to a nitrocellulose membrane and incubated with primary antibodies (1:1000 for anti-phospho-eNOS, Cell Signaling Technologies) and secondary horseradish peroxidase–conjugated antibodies (Amersham). The reactive proteins were detected by chemiluminescent reaction on Hyperfilms (Amersham).
Statistics
All data are expressed as mean±SEM. Repeated-measures ANOVAs (SPPS 10.0) were performed on raw data (after logarithmic transformation for homoscedasticity) to analyze differences between different treatments.
The EC50 (the concentration at which the effect is half-maximal) of NRG-1 and of the isoproterenol dose-response curves was calculated on raw data of active tension development with Graph Pad. EC50s of isoproterenol dose-response curves of the different treatments were analyzed with ANOVA followed by Bonferroni correction for multiple comparisons (SPPS 10.0). Differences were considered significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Effects of NRG-1 on Myocardial Contractility
Ninety minutes after its addition, NRG-1ß (100 ng/mL) significantly decreased peak twitch active tension by 18.6±2.6% versus baseline (from 42.6±9.0 to 35.2±8.0 mN/mm2, n=7, P<0.001) and peak rate of tension development by 11.0±5.0% versus baseline (from 286±49 to 255±45 mN · mm-2 · s-1, n=7, P<0.001), whereas in control muscles, these parameters remained unchanged. The onset of this negative inotropic response appeared within 30 minutes and persisted for at least 90 minutes (Figure 1A). Indomethacin, an inhibitor of the prostaglandin pathway, did not affect this negative inotropic effect (eg, at 90 minutes: active tension -26.1.1±3.4%, n=6, P=1 versus NRG-1ß alone, P<0.001 versus indomethacin alone). L-NMMA, an inhibitor of NOS significantly attenuated the response to NRG-1 (eg, at 90 minutes: active tension -2.0±3.7%, n=9, P=0.04 versus NRG-1ß alone, P=1.00 versus L-NMMA alone; Figure 1A), whereas genistein completely blocked the effect of NRG-1 (data not shown, n=5). After NRG-1ß was washed out, muscle performance partially recovered (NRG-1ß washed out at t=60 minutes; active tension at 60 minutes decreased 19.2±2.2% from baseline; 30 minutes after washout, active tension decreased only 9.2±1.2% from baseline; n=8). The response to NRG-1ß was dose dependent, with EC50 at 22.9±2.3 ng/mL (Figure 1B). Similar results were obtained for NRG-1
(Figure 1C).
|
NRG-1 also influenced myocardial performance under ß-adrenergic activation. Figure 1D shows that NRG-1ß significantly shifted the dose-response curve for isoproterenol to the right (logEC50 -6.91±0.08, n=10, in control versus -6.23±0.16, n=9, in the presence of NRG-1ß; P=0.01). This rightward shift was attenuated by L-NMMA (logEC50 -6.66±0.17, n=9, P=1.00 versus control, P=0.26 versus NRG-1ß), whereas L-NMMA in the absence of NRG-1ß had no effect (logEC50 -6.87±0.14, n=9). Similar results were observed for NRG-1 (data not shown).
NRG-1 Induces NO Production Through eNOS Activation
In NRCMs, NRG-1ß enhanced nitrite production from 73±3.3 to 90±5.4 nmol/mg protein (n=12, P=0.008; Figure 2A). Furthermore, immunoblot analyses showed that NRG-1ß induced a time-dependent phosphorylation of eNOS (Figure 2B) and of the serine/threonine kinase Akt (Figure 2C).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the present study, we demonstrated that NRG-1 affects myocardial contractility and activates NOS in cardiomyocytes. These observations add important information to the physiology of the NRG1/ErbB pathway.
First, we observed that both the - and ß-isoforms of NRG-1 induced a negative inotropic response in adult cardiac muscle. At first glance, this negative inotropic effect may appear in conflict with the putative protective actions of NRG-1 in the heart. A negative inotropic effect, however, should not be regarded as detrimental per se.3 It rather suggests that the NRG1/ErbB signaling pathway may have a modulatory role and could be activated in conditions of enhanced cardiac inotropism, such as in myocardial hypertrophy12 or during ß-adrenergic stimulation. Consistent with this conjecture, we observed that the inotropic effect of NRG-1 was preserved during adrenergic stimulation and desensitized the myocardium to isoproterenol. This negative inotropic effect may thus be beneficial, because it would lower myocardial oxygen consumption during stress. The negative inotropic actions of NRG-1 may also explain why the myocardium downregulates ErbB2 and ErbB4 at the onset of heart failure13 in an attempt to augment contractile performance.
NOS inhibition attenuated the effects of NRG-1 on myocardial contractility, whereas inhibition of the prostaglandin pathway had no effect. In cultured cardiomyocytes, NRG-1 enhanced release of nitrite. These observations suggest that the negative inotropic effect was mediated, at least in part, through NO. Apart from the prostaglandin pathway, however, the present data do not exclude the possibility that other pathways were involved.
In agreement with the report by Sawyer et al,14 we observed that NRG-1 activated Akt in cultured cardiomyocytes. Akt is a serine/threonine kinase involved in the phosphorylation of eNOS.15 The activation of eNOS is consistent with the observed negative inotropic effect, although the role of NO in the regulation of cardiac contractility appears somewhat conflicting.3 The inconsistent results in different studies can be explained in part by the recent discovery that the subcellular compartmentalization of NOS isoforms with effector molecules is important for NO signaling. eNOS can increase excitation-contraction coupling in T-tubular caveolae close to the sarcoplasmic reticulum in response to stretch while attenuating the ß-adrenergic response in caveolae that harbor ß-adrenoceptors.16 Consistent with the present report, activation of eNOS can thus depress contractility and reduce ß-adrenergic responsiveness.17 Not surprisingly, ErbB receptors colocalize with eNOS and ß-adrenergic receptors in caveolae.18 With respect to overall cardiac pump performance, activation of eNOS can have distinct beneficial effects through hastening of the onset of ventricular relaxation, enhancement of early rapid filling, and improvement in diastolic compliance.3 However, L-NMMA blocks other NOS isoforms; thus, we cannot attribute the inotropic effects of NRG-1 to a specific NOS isoform.
|
Acknowledgments |
|---|
Dr Lemmens was supported by a grant from the Fund for Scientific Research-Flanders (Belgium).
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 1215–1221.
2. Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med. 2003; 13: 80–86.[CrossRef][Medline] [Order article via Infotrieve]
3. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003; 83: 59–115.
4. Erickson SL, O’Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2 and heregulin-deficient mice. Development. 1997; 124: 4999–5011.[Abstract]
5. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002; 99: 8880–8885.
6. Baliga RR, Pimental DR, Zhao YY, et al. NRG-1-induced cardiomyocyte hypertrophy: role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol. 1999; 277: H2026–H2037.[Medline] [Order article via Infotrieve]
7. Fransen P, Hendrickx J, Brutsaert DL, et al. Distribution and role of Na(+)/K(+) ATPase in endocardial endothelium. Cardiovasc Res. 2001; 52: 487–499.
8. Brutsaert DL, Meulemans AL, Sipido KR, et al. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res. 1988; 62: 358–366.
9. Yamamoto K, Dang QN, Kennedy SP, et al. Induction of tenascin-C in cardiac myocytes by mechanical deformation: role of reactive oxygen species. J Biol Chem. 1999; 274: 21840–21846.
10. Ungureanu-Longrois D, Balligand JL, Simmons WW, et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to ß-adrenergic agonists. Circ Res. 1995; 77: 494–502.
11. Nawrocki-Raby B, Gilles C, Polette M, et al. E-cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am J Pathol. 2003; 163: 653–661.
12. Shorofsky SR, Agarwal R, Corretti M, et al. Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Circ Res. 1999; 84: 424–434.
13. Rohrbach S, Yan X, Weinberg EO, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis: differential expression of erbB2 and erbB4 receptors. Circulation. 1999; 100: 407–412.
14. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1ß and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002; 105: 1551–1554.
15. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2003; 284: R1–R12.
16. Maison PB, Feron C, Dessy C, et al. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003; 93: 388–398.
17. Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002; 416: 337–339.[Medline] [Order article via Infotrieve]
18. Feron O, Zhao YY, Kelly RA. The ins and outs of caveolar signaling: M2 muscarinic cholinergic receptors and eNOS activation versus neuregulin and ErbB4 signaling in cardiac myocytes. Ann N Y Acad Sci. 1999; 874: 11–19.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  G. Xu, T. Watanabe, Y. Iso, S. Koba, T. Sakai, M. Nagashima, S. Arita, S. Hongo, H. Ota, Y. Kobayashi, et al. Preventive Effects of Heregulin-{beta}1 on Macrophage Foam Cell Formation and Atherosclerosis Circ. Res., August 28, 2009; 105(5): 500 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ky, S. E. Kimmel, R. N. Safa, M. E. Putt, N. K. Sweitzer, J. C. Fang, D. B. Sawyer, and T. P. Cappola Neuregulin-1{beta} Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure Circulation, July 28, 2009; 120(4): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lemmens, K. Doggen, and G. W. De Keulenaer Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure Circulation, August 21, 2007; 116(8): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Chung and J. W. Walker Interaction and Inhibitory Cross-Talk between Endothelin and ErbB Receptors in the Adult Heart Mol. Pharmacol., June 1, 2007; 71(6): 1494 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lemmens, V. F. M. Segers, M. Demolder, and G. W. De Keulenaer Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talk J. Biol. Chem., July 14, 2006; 281(28): 19469 - 19477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-N. Giraud, M. Fluck, C. Zuppinger, and T. M. Suter Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1{beta} J Appl Physiol, July 1, 2005; 99(1): 313 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lemmens, V. F.M. Segers, G. W. De Keulenaer, K. Okoshi, M. Nakayama, X. Yan, M. P. Okoshi, A. J.T. Schuldt, B. H. Lorell, and M. A. Marchionni Letter Regarding Article by Okoshi et al, "Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of {beta}-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion" * Response Circulation, April 5, 2005; 111(13): e175 - e175. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ueda, A. Oikawa, A. Nakamura, F. Terasawa, K. Kawagishi, and T. Moriizumi Neuregulin Receptor ErbB2 Localization at T-tubule in Cardiac and Skeletal Muscle J. Histochem. Cytochem., January 1, 2005; 53(1): 87 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kuramochi, G. M. Cote, X. Guo, N. K. Lebrasseur, L. Cui, R. Liao, and D. B. Sawyer Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1{beta}/erbB4 Signaling J. Biol. Chem., December 3, 2004; 279(49): 51141 - 51147. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||